Welcome to China Oncology,
China Oncology ›› 2025, Vol. 35 ›› Issue (5): 505-509.doi: 10.19401/j.cnki.1007-3639.2025.05.009
• Original article • Previous Articles Next Articles
WANG Yilin(
), WANG Lu()
Received:2024-10-21
Revised:2025-03-23
Online:2025-05-30
Published:2025-06-10
Contact:
WANG Lu
Supported by:Share article
CLC Number:
WANG Yilin, WANG Lu. A comparative analysis of the long-term efficacy between partial hepatectomy and transcatheter arterial chemoembolization in patients with liver metastasis from nasopharyngeal carcinoma[J]. China Oncology, 2025, 35(5): 505-509.
Fig. 1
Flowchart of patient inclusion and exclusion criteria"
Tab. 1
Analysis of clinicopathological characteristics in 40 patients with NCLM [n （%）]"
| Characteristic | Resection group (n=20) | TACE group (n=20) | P value |
|---|---|---|---|
| Age/year median (range) | 52 (39-70) | 50 (38-70) | 0.905 |
| Gender | 0.607 | ||
| Male | 17 (85) | 16 (80) | |
| Female | 3 (15) | 4 (20) | |
| Liver metastasis presentation | 0.999 | ||
| Synchronous | 1 (5) | 1 (5) | |
| Metachronous | 19 (95) | 19 (95) | |
| Abdominal symptoms | 0.999 | ||
| Positive | 8 (40) | 8 (40) | |
| Negative | 12 (60) | 12 (60) | |
| Interval from NPC to hepatic metastasis/month | 0.809 | ||
| <12 | 5 (25) | 4 (20) | |
| ≥12 | 15 (75) | 16 (80) | |
| Epstein-Barr virus | 0.607 | ||
| Positive | 16 (80) | 17 (85) | |
| Negative | 4 (20) | 3 (15) | |
| HBsAg | 0.809 | ||
| Positive | 4 (20) | 5 (25) | |
| Negative | 16 (80) | 15 (75) |
Tab. 2
Comparative analysis of baseline characteristics and treatment parameters between resection group and TACE in 40 patients with NCLM [n （%）]"
| Item | Resection group (n=20) | TACE group (n=20) | P value |
|---|---|---|---|
| Lesion number | 0.998 | ||
| <3 | 16 (80) | 16 (80) | |
| ≥3 | 4 (20) | 4 (20) | |
| Size of largest metastasis/cm | 0.908 | ||
| <5 | 12 (60) | 13 (65) | |
| ≥5 | 8 (40) | 7 (35) | |
| Pathological type | 0.999 | ||
| Undifferentiated | 20 (100) | 20 (100) | |
| Other types | 0 (0) | 0 (0) | |
| Dose of radiotherapy/Gy median (range) | 0.437 | ||
| Nasopharyngeal | 69 (66-74) | 70 (66-76) | |
| Regional lymph node | 65 (51-69) | 66 (52-71) | |
| Adjuvant chemotherapy cycles of NPC | 0.809 | ||
| <3 | 16 (80) | 15 (75) | |
| ≥3 | 4 (20) | 5 (25) | |
| Preoperative /pre-TACE complications | |||
| Yes | 4 (20) | 4 (20) | 0.999 |
| No | 16 (80) | 16 (80) | |
| Postoperative/post-TACE complication | 0.607 | ||
| Yes | 3 (15) | 4 (20) | |
| No | 17 (85) | 16 (80) | |
| In-hospital mortality rate | 0 | 0 | 0.999 |
Fig. 2
Curve of cumulative mortality in hepatectomy group and TACE group"
| [1] | BRAY F, LAVERSANNE M, SUNG H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3): 229-263. |
| [2] |
WEI W I, SHAM J S. Nasopharyngeal carcinoma[J]. Lancet, 2005, 365(9476): 2041-2054.
doi: 10.1016/S0140-6736(05)66698-6 pmid: 15950718 |
| [3] |
JIN Y, CAI X Y, CAI Y C, et al. To build a prognostic score model containing indispensible tumour markers for metastatic nasopharyngeal carcinoma in an epidemic area[J]. Eur J Cancer, 2012, 48(6): 882-888.
doi: 10.1016/j.ejca.2011.09.004 pmid: 22030451 |
| [4] | LIU G Y, YE Y F, JIANG Y F, et al. Nab-paclitaxel, cisplatin, and capecitabine versus cisplatin and gemcitabine as first line chemotherapy in patients with recurrent or metastatic nasopharyngeal carcinoma: randomised phase 3 clinical trial[J]. BMJ, 2024, 385: e077890. |
| [5] | LI W Z, HUA X, LV S H, et al. A scoring system based on nutritional and inflammatory parameters to predict the efficacy of first-line chemotherapy and survival outcomes for de novo metastatic nasopharyngeal carcinoma[J]. J Inflamm Res, 2021, 14: 817-828. |
| [6] |
HUANG J, LI Q J, ZHENG Y, et al. Partial hepatectomy for liver metastases from nasopharyngeal carcinoma: a comparative study and review of the literature[J]. BMC Cancer, 2014, 14: 818.
doi: 10.1186/1471-2407-14-818 pmid: 25376591 |
| [7] |
FENG Y, ZHAO Y M, LI W W, et al. Hepatic resection prolongs overall survival in the selected patients with nasopharyngeal carcinoma liver metastases[J]. Eur J Surg Oncol, 2022, 48(10): 2202-2211.
doi: 10.1016/j.ejso.2022.05.033 pmid: 35691781 |
| [8] | ELIAS D, CAVALCANTI DE ALBUQUERQUE A, EGGENSPIELER P, et al. Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients[J]. J Am Coll Surg, 1998, 187(5): 487-493. |
| [9] |
WEITZ J, BLUMGART L H, FONG Y, et al. Partial hepatectomy for metastases from noncolorectal, nonneuroendocrine carcinoma[J]. Ann Surg, 2005, 241(2): 269-276.
doi: 10.1097/01.sla.0000150244.72285.ad pmid: 15650637 |
| [10] |
POL B, CAMPAN P, HARDWIGSEN J, et al. Morbidity of major hepatic resections: a 100-case prospective study[J]. Eur J Surg, 1999, 165(5): 446-453.
doi: 10.1080/110241599750006686 pmid: 10391161 |
| [11] |
COUINAUD C. Anatomic principles of left and right regulated hepatectomy: technics[J]. J Chir (Paris), 1954, 70(12): 933-966.
pmid: 13233306 |
| [12] |
KAWASAKI S, SUGIYAMA Y, IGA T, et al. Pharmacokinetic study on the hepatic uptake of indocyanine green in cirrhotic patients[J]. Am J Gastroenterol, 1985, 80(10): 801-806.
pmid: 4036939 |
| [13] |
CHUA D T T, SHAM J S T, AU G K H. A phase II study of capecitabine in patients with recurrent and metastatic nasopharyngeal carcinoma pretreated with platinum-based chemotherapy[J]. Oral Oncol, 2003, 39(4): 361-366.
doi: 10.1016/s1368-8375(02)00120-3 pmid: 12676255 |
| [14] | LILLO S, MIRANDOLA A, VAI A, et al. Current status and future directions of proton therapy for head and neck carcinoma[J]. Cancers (Basel), 2024, 16(11): 2085. |
| [15] | YU Y F, LU G Z, WANG R J, et al. Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma[J]. Front Immunol, 2024, 15: 1415246. |
| [16] | LIU Q X, WANG J F, SUN C P, et al. The diagnosis and management of rare cystic liver metastases from nasopharyngeal carcinoma: a case report[J]. Medicine (Baltimore), 2018, 97(26): e11257. |
| [17] | JUAREZ-VIGNON WHALEY J J, AFKHAMI M, ONYSHCHENKO M, et al. Recurrent/metastatic nasopharyngeal carcinoma treatment from present to future: where are we and where are we heading?[J]. Curr Treat Options Oncol, 2023, 24(9): 1138-1166. |
| [18] | DAI J X, ZHANG B, SU Y X, et al. Induction chemotherapy followed by radiotherapy vs chemoradiotherapy in nasopharyngeal carcinoma: a randomized clinical trial[J]. JAMA Oncol, 2024, 10(4): 456-463. |
| [19] | DI CARLO S, CAVALLARO G, ROVERE F L, et al. Synchronous liver and peritoneal metastases from colorectal cancer: is cytoreductive surgery and hyperthermic intraperitoneal chemotherapy combined with liver resection a feasible option?[J]. Front Surg, 2022, 9: 1006591. |
| [20] | POON R T, FAN S T, LO C M, et al. Improving perioperative outcome expands the role of hepatectomy in management of benign and malignant hepatobiliary diseases: analysis of 1 222 consecutive patients from a prospective database[J]. Ann Surg, 2004, 240(4): 698-708;discussion 708-710. |
| [21] | CHAMBERLAIN R S, CANES D, BROWN K T, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes?[J]. J Am Coll Surg, 2000, 190(4): 432-445. |
| [22] |
FONG Y, COHEN A M, FORTNER J G, et al. Liver resection for colorectal metastases[J]. J Clin Oncol, 1997, 15(3): 938-946.
doi: 10.1200/JCO.1997.15.3.938 pmid: 9060531 |
| [23] | DELIS S, BILIATIS I, BOURLI A, et al. Surgical resection of a solitary liver metastasis from nasopharyngeal carcinoma: a case report[J]. Hepatobiliary Pancreat Dis Int, 2006, 5(4): 610-612. |
| [24] | CHEN L, WU L X, ZHANG L J, et al. Effect of metformin on hepatocellular carcinoma patients with type Ⅱ diabetes receiving transarterial chemoembolization: a multicenter retrospective cohort study[J]. Int J Surg, 2025, 111(1): 828-838. |
| [25] | TAN E H, KHOO K S, WEE J, et al. Phase Ⅱ trial of a paclitaxel and carboplatin combination in Asian patients with metastatic nasopharyngeal carcinoma[J]. Ann Oncol, 1999, 10(2): 235-237. |
| [26] |
FOO K F, TAN E H, LEONG S S, et al. Gemcitabine in metastatic nasopharyngeal carcinoma of the undifferentiated type[J]. Ann Oncol, 2002, 13(1): 150-156.
doi: 10.1093/annonc/mdf002 pmid: 11865813 |
| [27] |
FANDI A, BACHOUCHI M, AZLI N, et al. Long-term disease-free survivors in metastatic undifferentiated carcinoma of nasopharyngeal type[J]. J Clin Oncol, 2000, 18(6): 1324-1330.
doi: 10.1200/JCO.2000.18.6.1324 pmid: 10715304 |
| [28] | TREHUB Y, MALOVANNA A, ZEMSKOV S. The current state of perioperative chemotherapy in resectable colorectal liver metastases: a narrative review[J]. J Surg Oncol, 2025. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
沪ICP备12009617
Powered by Beijing Magtech Co. Ltd
